isogenica



Dr Björn Cochlovius appointed as Chairman of Isogenica Board of Directors

Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the "Board") will retire from the Board effective 31 December 2019. He will be succeeded by Dr Björn Cochlovius, currently a Non-Executive Director of Isogenica Ltd., who has been named Chairman of the Board, effective 1 January 2020.


Björn Cochlovius most recently served as Asia-Pacific Head of Development (Strategy) at Abbvie and brings more than 20 years of biopharmaceutical discovery, clinical development and commercial experience to the Board.

In his role as Chairman, Dr Cochlovius will work closely with the CEO and leadership team to prioritize and deliver ongoing expansion and business development activities, form new strategic relationships and build investor relations.

Read the full press release



CEO Emma Sceats and Director of Business Development, David Mead will be attending Biotech Showcase 2020. Get in touch to learn how Isogenica can accelerate discovery of single domain LlamdA™ VHH antibodies for bi- and multispecifics, ADCs, cell and gene therapies. Contact bd@isogenica.com to organise a meeting.





Working in collaboration with biopharmaceutical partners over the last decade Isogenica has developed a deep pipeline including one clinical stage asset and eleven partnered pre-clinical and discovery stage programmes. Learn more about <u>partnering</u> with Isogenica.







Isogenica is a drug discovery company focusing on the design and build of diverse, fully synthetic, antibody libraries for use in biopharmaceutical discovery.

Your data is important to us. View our privacy policy here

Our mailing address is: info@isogenica.com

Want to change how you receive these emails? You can <u>unsubscribe from this list</u>.

This email was sent to *|EMAIL|*

why did I get this? unsubscribe from this list update subscription preferences

|LIST:ADDRESSLINE|